Declan T Barry1, Brandon D L Marshall2, William C Becker3, Adam J Gordon4, Stephen Crystal5, Robert D Kerns3, Julie R Gaither6, Kirsha S Gordon3, Amy C Justice3, David A Fiellin7, E Jennifer Edelman7. 1. Yale School of Medicine, New Haven, CT, 06510, USA; APT Foundation Pain Treatment Services, New Haven, CT, 06519, USA. Electronic address: declan.barry@yale.edu. 2. Brown School of Public Health, Providence, RI, 02903, USA. 3. Yale School of Medicine, New Haven, CT, 06510, USA; VA Connecticut Healthcare System, West Haven, CT, 06516, USA. 4. University of Utah School of Medicine, Salt Lake City, UT, 84148, USA. 5. Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, NJ, 08901, USA. 6. Yale School of Medicine, New Haven, CT, 06510, USA. 7. Yale School of Medicine, New Haven, CT, 06510, USA; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, 06510, USA.
Abstract
BACKGROUND/AIMS: Although nonmedical use of prescription opioids (NMUPO) is a public health problem, few studies have examined the new-onset NMUPO in clinical populations. We estimated NMUPO incidence among veterans in medical care who had received prescription opioid medication and examined correlates of new-onset NMUPO. DESIGN: Prospective cohort study. SETTING: Veterans Health Administration primary care and infectious disease clinics in Atlanta, Baltimore, Bronx, Houston, Los Angeles, Manhattan, Pittsburgh, and Washington, DC. PARTICIPANTS: Patients enrolled in the Veterans Aging Cohort Study wave 3 (2005-2007) who received prescription opioids in the previous year and without lifetime NMUPO were followed at waves 4 and 5 (2008-2011). MEASUREMENTS: Cox proportional hazards regression was used to examine the relationship between duration of prescription opioid receipt and incident NMUPO, adjusting for demographics, alcohol and tobacco use, substance use disorders, psychiatric and medical diagnoses, and medication-related characteristics. FINDINGS: Among eligible participants (n = 815), the median age was 52 (IQR = 47-58) and 498 (59.8%) were Black; 122 (15.0%) reported new-onset NMUPO, for an incidence rate of 5.0 per 100 person-years. In a multivariable Cox model, compared to <30 days, receipt of prescription opioids for 30-180 days (adjusted hazard ratio [AHR] = 1.65 95% CI: 1.06, 2.58) or >180 days (AHR = 1.99, 95% CI: 1.21, 3.29) was associated with incident NMUPO. CONCLUSIONS: Duration of prescription opioid receipt is a risk factor for incident NMUPO among veterans receiving medical care. Providers who prescribe opioids should monitor for NMUPO, especially among those with a longer duration of opioid therapy.
BACKGROUND/AIMS: Although nonmedical use of prescription opioids (NMUPO) is a public health problem, few studies have examined the new-onset NMUPO in clinical populations. We estimated NMUPO incidence among veterans in medical care who had received prescription opioid medication and examined correlates of new-onset NMUPO. DESIGN: Prospective cohort study. SETTING: Veterans Health Administration primary care and infectious disease clinics in Atlanta, Baltimore, Bronx, Houston, Los Angeles, Manhattan, Pittsburgh, and Washington, DC. PARTICIPANTS: Patients enrolled in the Veterans Aging Cohort Study wave 3 (2005-2007) who received prescription opioids in the previous year and without lifetime NMUPO were followed at waves 4 and 5 (2008-2011). MEASUREMENTS: Cox proportional hazards regression was used to examine the relationship between duration of prescription opioid receipt and incident NMUPO, adjusting for demographics, alcohol and tobacco use, substance use disorders, psychiatric and medical diagnoses, and medication-related characteristics. FINDINGS: Among eligible participants (n = 815), the median age was 52 (IQR = 47-58) and 498 (59.8%) were Black; 122 (15.0%) reported new-onset NMUPO, for an incidence rate of 5.0 per 100 person-years. In a multivariable Cox model, compared to <30 days, receipt of prescription opioids for 30-180 days (adjusted hazard ratio [AHR] = 1.65 95% CI: 1.06, 2.58) or >180 days (AHR = 1.99, 95% CI: 1.21, 3.29) was associated with incident NMUPO. CONCLUSIONS: Duration of prescription opioid receipt is a risk factor for incident NMUPO among veterans receiving medical care. Providers who prescribe opioids should monitor for NMUPO, especially among those with a longer duration of opioid therapy.
Authors: Anees Bahji; Yu Li; Rachel Vickers-Smith; Stephen Crystal; Robert D Kerns; Kirsha S Gordon; Alexandria Macmadu; Melissa Skanderson; Kaku So-Armah; Minhee L Sung; Fiona Bhondoekhan; Brandon D L Marshall; E Jennifer Edelman Journal: Int J Environ Res Public Health Date: 2022-05-06 Impact factor: 4.614
Authors: Chung Jung Mun; Patrick H Finan; Michael T Smith; C Patrick Carroll; Joshua M Smyth; Sophie M Lanzkron; Jennifer A Haythornthwaite; Claudia M Campbell Journal: Ann Behav Med Date: 2021-06-02
Authors: Janni Leung; Gary C K Chan; Samuel X Tan; Caitlin McClure-Thomas; Louisa Degenhardt; Wayne Hall Journal: Int J Environ Res Public Health Date: 2022-03-23 Impact factor: 3.390
Authors: E Jennifer Edelman; Yu Li; Declan Barry; Jennifer Brennan Braden; Stephen Crystal; Robert D Kerns; Julie R Gaither; Kirsha S Gordon; Ajay Manhapra; Jessica S Merlin; Brent A Moore; Benjamin J Oldfield; Lesley S Park; Christopher T Rentsch; Melissa Skanderson; Emily C Williams; Amy C Justice; Janet P Tate; William C Becker; Brandon D L Marshall Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771